Insider Ledger
PVCT insider buying and SEC filings, explained
Provectus Biopharmaceuticals, Inc. · CIK 315545
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- OTC
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- PROVECTUS PHARMACEUTICALS INC; PROVECTUS PHARMACEUTICAL INC; ZAMAGE DIGITAL IMAGING INC; SPM GROUP INC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Feb 9, 2026 | Other purchase | Edward Pershing (CEO and Director) bought 34,940 Series D-1 Convertible Preferred Stock at $2.86 ($100K), reported as a purchase (code P). Holdings up 1% to 2,613,807 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 11, 2026 |
37 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PVCT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.